CD19 and neoplasm: By using fluorochrome-labeled anti-CD19 or anti-CD3 antibodies in the flow cytometry analysis, tumor cell lines Daudi, Raji, and Raji/eGFP-fLuc were shown to be positive for CD19 expression on the cell surface (Fig. 2b, d, f), and the expanded human γ9δ2 T cells were positive for CD3 expression on the cell surface (Fig. 2k); RPMI-8226 was negative for the surface expression of CD3 or CD19 (Fig. 2h, i).